Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KURIAN C ABRAHAM

Allopathic & Osteopathic Physicians Psychiatry & Neurology Geriatric Psychiatry

NPI
1891754297
CMS profile
85878
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,166.11

61 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,161.19 60
Education $4.92 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–61 of 61 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KURIAN C ABRAHAM

NPI 1891754297 · CMS profile ID 85878

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Geriatric Psychiatry

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–61 of 61 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1891754297?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KURIAN C ABRAHAM, NPI 1891754297, CMS profile ID 85878. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–61 of 61 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891754297?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). KURIAN C ABRAHAM, NPI 1891754297, CMS profile ID 85878. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–61 of 61 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891754297?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
KURIAN C ABRAHAM, NPI 1891754297, CMS profile ID 85878, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–61 of 61 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1891754297?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

61 matching records · $1,166.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 61 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–61 of 61.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Supernus Pharmaceuticals, Inc. $14.0603/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053188967 CMS
AbbVie Inc. $23.0603/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996082263 CMS
Axsome Therapeutics, Inc. $22.3702/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056175829 CMS
IDORSIA PHARMACEUTICALS US INC $18.4402/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038226477 CMS
Otsuka America Pharmaceutical, Inc. $5.2702/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014164781 CMS
Lundbeck LLC $18.7402/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032158787 CMS
Teva Pharmaceuticals USA, Inc. $22.3402/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056702077 CMS
AbbVie Inc. $23.7502/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996082261 CMS
Axsome Therapeutics, Inc. $22.1102/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056175823 CMS
AbbVie Inc. $16.9501/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996082259 CMS
Otsuka America Pharmaceutical, Inc. $4.9201/11/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014164773 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,053.36 39
PY2020 $788.41 48
PY2021 $326.58 18
PY2022 $869.63 48
PY2023 $1,166.11 61
PY2024 $1,074.81 53
PY2025 $2,071.95 86

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $767,499.07 70
PY2024 Principal investigator $811,841.44 112
PY2023 Principal investigator $1,084,481.73 177
PY2022 Principal investigator $545,916.77 78
PY2021 Principal investigator $946,819.01 93
PY2020 Principal investigator $976,061.47 115
PY2019 Recipient $286.19 3
PY2019 Principal investigator $495,055.62 41

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

70 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,132.24 12/31/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects with Generalized Anxiety Disorder who have had an Inadequate Response to Antidepressant Therapies No dispute reported 06/30/2026 1202533269
Principal investigator 1 ABBVIE INC. $1,222.42 12/31/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
Multicenter, Open-label Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder No dispute reported 06/30/2026 1202533445
Principal investigator 1 ABBVIE INC. $3,978.04 12/31/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder No dispute reported 06/30/2026 1202533447
Principal investigator 1 ABBVIE INC. $9,164.76 12/04/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202526658
Principal investigator 1 ABBVIE INC. $9,136.98 12/04/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202527680
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,112.00 12/01/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH
ITI-1284-201 No dispute reported 06/30/2026 1242368265
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,112.00 12/01/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH
ITI-1284-201 No dispute reported 06/30/2026 1242368267
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,112.00 12/01/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH
ITI-1284-201 No dispute reported 06/30/2026 1242368269
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,297.00 12/01/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH
ITI-1284-201 No dispute reported 06/30/2026 1242368271
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,198.00 12/01/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH
ITI-1284-201 No dispute reported 06/30/2026 1242368273
Principal investigator 1 Novo Nordisk AS $4,165.00 11/20/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213820062
Principal investigator 1 ABBVIE INC. $6,035.23 11/07/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202523591
Principal investigator 1 ABBVIE INC. $19,783.62 11/05/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202521509
Principal investigator 1 ABBVIE INC. $12,485.61 11/05/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202521511
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,555.00 11/05/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH
ITI-1284-201 No dispute reported 06/30/2026 1242365713
Principal investigator 1 Novo Nordisk AS $3,548.41 10/29/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213835111
Principal investigator 1 ABBVIE INC. $1,638.48 10/17/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202517435
Principal investigator 1 ABBVIE INC. $4,178.90 10/09/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202514453
Principal investigator 1 ABBVIE INC. $22,663.33 10/09/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202514455
Principal investigator 1 ABBVIE INC. $500.00 10/08/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202513577
Principal investigator 1 Celgene Corporation $6,000.00 10/08/2025 Non-covered Recipient Entity
New Hope Clinical Research
A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease No dispute reported 06/30/2026 1222305686
Principal investigator 1 Janssen Research & Development, LLC $1,850.00 10/03/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open-label Long-term Extension Treatment with Aticaprant No dispute reported 06/30/2026 1175345826
Principal investigator 1 Janssen Research & Development, LLC $3,999.00 10/03/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open-label Long-term Extension Treatment with Aticaprant No dispute reported 06/30/2026 1175345841
Principal investigator 1 Janssen Research & Development, LLC $5,570.00 09/29/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175345865
Principal investigator 1 ABBVIE INC. $6,308.96 09/04/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202509456
Principal investigator 1 ABBVIE INC. $41,970.50 09/04/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202509458
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $96,990.00 08/21/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244041269
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,808.00 08/14/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244041267
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $525.00 08/07/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244041265
Principal investigator 1 ABBVIE INC. $11,714.02 08/06/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202503299
Principal investigator 1 ABBVIE INC. $20,722.89 08/06/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202503301
Principal investigator 1 ABBVIE INC. $10,062.00 08/06/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder No dispute reported 06/30/2026 1202503303
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $106,097.57 07/31/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244041263
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,356.38 07/28/2025 Non-covered Recipient Entity
New Hope Clinical Research-tammy Rader
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder No dispute reported 06/30/2026 1235995389
Principal investigator 1 Novo Nordisk AS $4,190.00 07/16/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213778020
Principal investigator 1 Novo Nordisk AS $831.74 07/16/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213807889
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,598.36 06/24/2025 Non-covered Recipient Entity
New Hope Clinical Research-tammy Rader
A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease No dispute reported 06/30/2026 1235995387
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $13,725.00 06/05/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244041261
Principal investigator 1 ABBVIE INC. $5,982.08 06/03/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202488223
Principal investigator 1 ABBVIE INC. $9,825.00 06/03/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder No dispute reported 06/30/2026 1202488225
Principal investigator 1 Janssen Research & Development, LLC $889.00 05/21/2025 Non-covered Recipient Entity
New Hope Clinic Rsrch
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175238980
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,366.87 05/08/2025 Non-covered Recipient Entity
New Hope Clinical Research-tammy Rader
A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease No dispute reported 06/30/2026 1235995385
Principal investigator 1 ABBVIE INC. $11,027.00 05/07/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202484077
Principal investigator 1 ABBVIE INC. $19,160.24 05/07/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202484079
Principal investigator 1 Janssen Research & Development, LLC $4,514.00 04/28/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175345874
Principal investigator 1 Janssen Research & Development, LLC $6,997.00 04/23/2025 Non-covered Recipient Entity
New Hope Clinic Rsrch
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175238972
Principal investigator 1 Novo Nordisk AS $2,201.94 04/21/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213804183
Principal investigator 1 ABBVIE INC. $2,034.16 04/16/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1202477164
Principal investigator 1 ABBVIE INC. $48,542.88 04/03/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202470001
Principal investigator 1 Janssen Research & Development, LLC $24,843.00 04/02/2025 Non-covered Recipient Entity
New Hope Clinic Rsrch
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175239072
Principal investigator 1 ABBVIE INC. $1,500.00 04/01/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1202468032
Principal investigator 1 Janssen Research & Development, LLC $6,865.00 03/31/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175345851
Principal investigator 1 ABBVIE INC. $9,527.69 03/19/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202464589
Principal investigator 1 Sumitomo Pharma America, Inc. $949.40 03/19/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH
A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. No dispute reported 06/30/2026 1176630575
Principal investigator 1 ABBVIE INC. $44,891.54 03/07/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
M23-894 - Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202462039
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,000.00 03/05/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 1242334618
Principal investigator 1 Janssen Research & Development, LLC $11,242.00 03/03/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175345818
Principal investigator 1 ABBVIE INC. $11,846.24 02/06/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
M23-894 - Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202447857
Principal investigator 1 Novo Nordisk AS $831.74 01/31/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213735518
Principal investigator 1 Janssen Research & Development, LLC $13,239.00 01/24/2025 Non-covered Recipient Entity
New Hope Clinic Rsrch
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175238889
Principal investigator 1 Sumitomo Pharma America, Inc. $1,500.00 01/22/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH
A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. No dispute reported 06/30/2026 1176624465
Principal investigator 1 Sumitomo Pharma America, Inc. $3,476.00 01/22/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH
A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. No dispute reported 06/30/2026 1176624472
Principal investigator 1 Sumitomo Pharma America, Inc. $1,026.00 01/22/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH
A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. No dispute reported 06/30/2026 1176624479
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,520.67 01/21/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244041259
Principal investigator 1 Janssen Research & Development, LLC $18,620.00 01/17/2025 Non-covered Recipient Entity
New Hope Clinic Rsrch
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1175239058
Principal investigator 1 Janssen Research & Development, LLC $770.00 01/13/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175345811
Principal investigator 1 Janssen Research & Development, LLC $25,420.00 01/13/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175345833
Principal investigator 1 Janssen Research & Development, LLC $7,504.00 01/13/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175345858
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $498.96 01/07/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244041255
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,549.22 01/07/2025 Non-covered Recipient Entity
NEW HOPE CLINICAL RESEARCH INC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244041257